These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17110029)

  • 1. Metformin therapy in a transgenic mouse model of Huntington's disease.
    Ma TC; Buescher JL; Oatis B; Funk JA; Nash AJ; Carrier RL; Hoyt KR
    Neurosci Lett; 2007 Jan; 411(2):98-103. PubMed ID: 17110029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease.
    Josefsen K; Nielsen MD; Jørgensen KH; Bock T; Nørremølle A; Sørensen SA; Naver B; Hasholt L
    J Neuroendocrinol; 2008 Feb; 20(2):165-72. PubMed ID: 18034868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
    Zádori D; Geisz A; Vámos E; Vécsei L; Klivényi P
    Pharmacol Biochem Behav; 2009 Nov; 94(1):148-53. PubMed ID: 19698736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.
    Giampà C; Middei S; Patassini S; Borreca A; Marullo F; Laurenti D; Bernardi G; Ammassari-Teule M; Fusco FR
    Eur J Neurosci; 2009 Mar; 29(5):902-10. PubMed ID: 19291221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel substituted pyrimidine, KP544, reduces motor deficits in the R6/2 transgenic mouse model of Huntington's disease.
    Dey ND; Boersen AJ; Myers RA; York LR; Bombard MC; Lu M; Sandstrom MI; Hulce VD; Lescaudron L; Dunbar GL
    Restor Neurol Neurosci; 2007; 25(5-6):485-92. PubMed ID: 18334766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice.
    Bolivar VJ; Manley K; Messer A
    Brain Res; 2004 Apr; 1005(1-2):29-35. PubMed ID: 15044061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation.
    Hernández-Espinosa D; Morton AJ
    Brain Res Bull; 2006 May; 69(6):669-79. PubMed ID: 16716837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGF-1 protects against diabetic features in an in vivo model of Huntington's disease.
    Duarte AI; Petit GH; Ranganathan S; Li JY; Oliveira CR; Brundin P; Björkqvist M; Rego AC
    Exp Neurol; 2011 Oct; 231(2):314-9. PubMed ID: 21763311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
    Conforti P; Ramos C; Apostol BL; Simmons DA; Nguyen HP; Riess O; Thompson LM; Zuccato C; Cattaneo E
    Mol Cell Neurosci; 2008 Sep; 39(1):1-7. PubMed ID: 18571429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease.
    Pang TY; Du X; Zajac MS; Howard ML; Hannan AJ
    Hum Mol Genet; 2009 Feb; 18(4):753-66. PubMed ID: 19008301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD.
    Glynn D; Reim K; Brose N; Morton AJ
    Brain Res Bull; 2007 Apr; 72(2-3):108-20. PubMed ID: 17352934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
    Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
    Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice.
    Denovan-Wright EM; Attis M; Rodriguez-Lebron E; Mandel RJ
    J Neurosci Res; 2008 Jun; 86(8):1748-57. PubMed ID: 18293418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased thirst and drinking in Huntington's disease and the R6/2 mouse.
    Wood NI; Goodman AO; van der Burg JM; Gazeau V; Brundin P; Björkqvist M; Petersén A; Tabrizi SJ; Barker RA; Morton AJ
    Brain Res Bull; 2008 May; 76(1-2):70-9. PubMed ID: 18395613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase.
    Bailey CD; Johnson GV
    Neurobiol Aging; 2006 Jun; 27(6):871-9. PubMed ID: 15896882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation.
    Wade A; Jacobs P; Morton AJ
    Brain Res; 2008 Jan; 1188():61-8. PubMed ID: 18062944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The detection and measurement of locomotor deficits in a transgenic mouse model of Huntington's disease are task- and protocol-dependent: influence of non-motor factors on locomotor function.
    Pallier PN; Drew CJ; Morton AJ
    Brain Res Bull; 2009 Mar; 78(6):347-55. PubMed ID: 19010400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of early behavioral markers of Huntington's disease in R6/2 mice employing an automated social home cage.
    Rudenko O; Tkach V; Berezin V; Bock E
    Behav Brain Res; 2009 Nov; 203(2):188-99. PubMed ID: 19410605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.
    Zourlidou A; Gidalevitz T; Kristiansen M; Landles C; Woodman B; Wells DJ; Latchman DS; de Belleroche J; Tabrizi SJ; Morimoto RI; Bates GP
    Hum Mol Genet; 2007 May; 16(9):1078-90. PubMed ID: 17360721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.
    Gil JM; Rego AC
    Brain Res Rev; 2009 Mar; 59(2):410-31. PubMed ID: 19118572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.